HTB-26 MDA-MB-231 人乳腺癌细胞

ATCC® Number:  HTB-26™    Designations:  MDA-MB-231  
Depositors:   R Cailleau  
Biosafety Level: 1  
Shipped:  frozen  
Medium & Serum:  See Propagation  
Growth Properties: adherent 
Organism: Homo sapiens （human）  
Morphology: epithelial

HTB-26 MDA-MB-231 人乳腺癌细胞 
Source: Organ: mammary gland; breast 
Disease: adenocarcinoma 
Derived from metastatic site: pleural effusion 
Cell Type: epithelial 
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.  
HTB-26  
Applications: transfection host （Nucleofection technology from Lonza
Roche FuGENE® Transfection Reagents） 
Receptors: epidermal growth factor （EGF）, expressed 
transforming growth factor alpha （TGF alpha）, expressed 
Tumorigenic: Yes  
DNA Profile （STR）: Amelogenin: X 
CSF1PO: 12,13 
D13S317: 13 
D16S539: 12 
D5S818: 12 
D7S820: 8,9 
THO1: 7,9.3 
TPOX: 8,9 
vWA: 15,18 
Cytogenetic Analysis: The cell line is aneuploid female （modal number = 64, range = 52 to 68）, with chromosome counts in the near-triploid range. Normal chromosomes N8 and N15 were absent. Eleven stable rearranged marker chromosomes are noted as well as unassignable chromosomes in addition to the majority of autosomes that are trisomic. Many of the marker chromosomes are identical to those shown in the karyotype reported by K.L. Satya-Prakash, et al. 
Isoenzymes:  AK-1, 1 
ES-D, 1 
G6PD, B 
GLO-I, 2 
Me-2, 1-2 
PGM1, 1-2 
PGM3, 1 
Age:  51 years adult  
Gender:  female  
Ethnicity:  Caucasian  
Comments: The cells express the WNT7B oncogene [PubMed: 8168088]. 
Propagation:  ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Leibovitz's L-15 Medium, Catalog No. 30-2008. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 100% 
Temperature: 37.0°C 
Subculturing:  Protocol: 
Remove and discard culture medium.
Briefly rinse the cell layer with 0.25% （w/v） Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed （usually within 5 to 15 minutes）.
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
Add appropriate aliquots of the cell suspension to new culture vessels.
Incubate cultures at 37°C without CO2.

Subc*tion Ratio: A subc*tion ratio of 1:2 to 1:4 is recommended 
Medium Renewal: 2 to 3 times per week 
Preservation:  Freeze medium: Complete growth medium supplemented with 5% （v/v） DMSO 
Storage temperature: liquid nitrogen vapor phase 
Related Products: Recommended medium （without the additional supplements or serum described under ATCC Medium）:ATCC 30-2008
recommended serum:ATCC 30-2020
purified DNA:ATCC 45518
purified DNA:ATCC 45519
purified DNA:ATCC HTB-26D
purified RNA:ATCC HTB-26R 
References: 1206: Brinkley BR, et al. Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro. Cancer Res. 40: 3118-3129, 1980. PubMed: 7000337
22182: Cruciger Q, et al. Morphological, biochemical and chromosomal characterization of breast tumor lines from pleural effusions. In Vitro 12: 331, 1976.
22429: Siciliano MJ, et al. Mutually exclusive genetic signatures of human breast tumor cell lines with a common chromosomal marker. Cancer Res. 39: 919-922, 1979. PubMed: 427779
22532: Cailleau R, et al. Breast tumor cell lines from pleural effusions. J. Natl. Cancer Inst. 53: 661-674, 1974. PubMed: 4412247
22656: Cailleau R, et al. Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 14: 911-915, 1978. PubMed: 730202
22977: Bates SE, et al. Expression of the transforming growth factor-alpha/epidermal growth factor receptor pathway in normal human breast epithelial cells. Endocrinology 126: 596-607, 1990. PubMed: 2294006
23010: Dickstein B, et al. Increased epidermal growth factor receptor in an estrogen-responsive, adriamycin-resistant MCF-7 cell line. J. Cell. Physiol. 157: 110-118, 1993. PubMed: 8408230
23113: Huguet EL, et al. Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res. 54: 2615-2621, 1994. PubMed: 8168088
26321: Satya-Prakash KL, et al. Cytogenetic analysis on eight human breast tumor cell lines: high frequencies of 1q, 11q and HeLa-like marker chromosomes. Cancer Genet. Cytogenet. 3: 61-73, 1981. PubMed: 7272986
32272: Katayose Y, et al. Promoting apoptosis: a novel activity associated with the Cyclin-dependent kinase inhibitor p27. Cancer Res. 57: 5441-5445, 1997. PubMed: 9407946
32275: Littlewood-Evans AJ, et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. 57: 5386-5390, 1997. PubMed: 9393764
32341: Sheng S, et al. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc. Natl. Acad. Sci. USA 93: 11669-11674, 1996. PubMed: 8876194
32489: De Vincenzo R, et al. Antiproliferative activity of colchicine analogues on MDR-positive and MDR-negative human cancer cell lines. Anticancer Drug Des. 13: 19-33, 1998. PubMed: 9474240
33021: Soker S, et al. Characterization of novel vascular endothelial growth factor （VEGF） receptors on tumor cells that bind VEGF165 via its exon 7-endoded domain. J. Biol. Chem. 271: 5761-5767, 1996. PubMed: 8621443

HTB-26

HTB-26

HTB-26